Fortitude Family Office’s Crescent Biopharma CBIO Stock Holding History

Fortitude Family Office’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$720	Hold	40	–	–	﹤0.01%	1871
2026 Q1	$735	Buy	+40	New	+$459	﹤0.01%	1589

Other funds holding CBIO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Fortitude Family Office's CBIO Position: Q2 2026 in Review

Fortitude Family Office held its Crescent Biopharma (CBIO) position steady in Q2 2026 at 40 shares worth $720. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Fortitude Family Office first reported a position in CBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $735 in Q1 2026. 8 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Fortitude Family Office held 40 shares of Crescent Biopharma worth $720 as of Q2 2026.
Fortitude Family Office left its Crescent Biopharma share count unchanged in Q2 2026.
Crescent Biopharma made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1871 holding.
Fortitude Family Office first reported a position in Crescent Biopharma in Q1 2026 and has held it in 2 quarters since.
Fortitude Family Office's Crescent Biopharma position peaked at $735 in Q1 2026.
8 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.